|
|
Post by letitride on Aug 9, 2024 8:26:06 GMT -5
On a more serious note what percent of analyst actually read the 10Q if any? If someone is analyzing the companies past present and future it seems imperative.
|
|
|
|
Post by radgray68 on Aug 9, 2024 12:02:58 GMT -5
I vote for Inhaled cancer fighting nano bots 😏
ps Powered by AI
|
|
|
|
Post by porkini on Aug 9, 2024 12:21:02 GMT -5
|
|
|
|
Post by ktim on Aug 9, 2024 15:16:29 GMT -5
Maybe with gene editing they could make a kosher pig  For some reason I suspect that joke should violate at least one of the boards rules... ooops. Though I do like the idea of a movie franchise "Planet of the Pigs" whose genesis is AI pigs from UTHRs research. |
|
|
|
Post by ktim on Aug 9, 2024 15:20:25 GMT -5
On a more serious note what percent of analyst actually read the 10Q if any? If someone is analyzing the companies past present and future it seems imperative. Any real analyst would put it under a microscope. I'm just an investor and I've read a lot of 10Qs over the years... skipping over stuff I know is boilerplate or cut and paste from previous 10Qs. |
|
|
|
Post by hellodolly on Aug 20, 2024 14:28:42 GMT -5
I see LQDA had about four downgrades today to their SP and UTHR upgrades. Mike should call his friends over at Cantor and other houses that cover MNKD and remind them that MNKD manufactures Tyvaso, DPI and is therefore a second tier derivative beneficiary play on the LQDA news???
|
|
|
|
Post by sportsrancho on Aug 24, 2024 7:04:19 GMT -5
The stock has been over five dollars for a while now …time for CNBC?
|
|
|
|
Post by mayday on Aug 24, 2024 8:31:22 GMT -5
The stock has been over five dollars for a while now …time for CNBC? Make it happen sports! Take one for the team! |
|
|
|
Post by sla55 on Aug 28, 2024 7:50:20 GMT -5
www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-mannkind-mnkd-2Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)
In a report released today, Andreas Argyrides from Oppenheimer maintained a Buy rating on MannKind (MNKD – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $5.38. According to TipRanks, Argyrides is a 4-star analyst with an average return of 10.0% and a 49.05% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as United Therapeutics, Clearside Biomedical, and Sarepta Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for MannKind with a $8.00 average price target. Based on MannKind’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $72.39 million and a GAAP net loss of $2.01 million. In comparison, last year the company earned a revenue of $48.61 million and had a GAAP net loss of $5.27 million
|
|
|
|
Post by factspls88 on Aug 28, 2024 9:17:58 GMT -5
🙏🤞
|
|
|
|
Post by castlerockchris on Aug 28, 2024 9:57:21 GMT -5
I sure hope Andrea’s is right, but let’s be honest, an analyst with his track record, reiterating his buy rated does not move a stock 12% in a day. I’m hoping something much bigger is afoot. But then again I have had this same hope for over a decade. Seems like things are finally falling into place. 🤞
|
|
|
|
Post by thekid2499 on Aug 28, 2024 10:04:55 GMT -5
Yes, volume would seem to indicate something else is going on, but who knows!
|
|
|
|
Post by cjm18 on Aug 28, 2024 10:25:56 GMT -5
As of the second quarter of 2024, **Tyvaso** generated **$398.2 million** in revenue, representing a 25% increase from the same quarter in 2023. The drug is expected to reach peak sales of **$5 billion** by 2033, particularly due to its potential expansion into treating idiopathic pulmonary fibrosis (IPF) in addition to its current use for pulmonary arterial hypertension [oai_citation:2,MannKind shares target raised on TYVASO outlook By Investing.com](https://www.investing.com/news/company-news/mannkind-shares-target-raised-on-tyvaso-outlook-93CH-3590920) [oai_citation:1,Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD) | Markets Insider](https://markets.businessinsider.com/news/stocks/oppenheimer-reaffirms-their-buy-rating-on-mannkind-mnkd-1032920834).
|
|
|
|
Post by mayday on Sept 9, 2024 8:28:13 GMT -5
|
|
|
|
Post by ronw77077 on Nov 8, 2024 19:31:38 GMT -5
Per NASDAQ (Nov. 8, 2024):
Analyst Price Targets Based on the following firms:
CANTOR FITZGERALD
H C WAINWRIGHT
LEERINK
OPPENHEIMER HLD
WEDBUSH SECURITIES
CONSENSUS $9.5
Based on analysts offering 12 month price targets for MNKD in the last 3 months. The average price target is $9.5 with a high estimate of $12 and a low estimate of $7.
In addition:
RBC raised its price target from $5 to $7 (finally)
Rodman & Renshaw have raised their price target today on MNKD from $8 to $10
|
|
